"Synergies between both sites will be progressively activated in order to further enhance reactivity and flexibility to meet the requests of new and existing clients, while maintaining the highest regulatory and quality assurance level," according to an EP statement. EP controls four operational subsidiaries:
- Sodia (Reims) - Contract manufacturing and the marketing of existing pharmaceutical products and clinical supplies
- Creapharm (Bordeaux) - Production and distribution of investigational medicinal products and devices
- Stradis (Reims) - Contract manufacturing of pharmaceutical products
- Onyligne (Beauvais) - Contract development and manufacturing of cosmetic and hygiene products
Michel Pautrat, the former president of Creapharm, noted, "This sale affords Creapharm access to additional resources in order to better serve clients in France, and will ensure increased visibility to attract European clients. It also creates a very strong pharmaceutical platform for International promoters who need to conduct clinical studies in Europe"
Eric Placet, the founder of EP Finance, added, "This strategic acquisition complements the offering of the group to pharmaceutical clients, and enables us to become one of the key actors for clinical supplies in Europe. We are most satisfied to be in a position to synergize the capabilities of Creapharm and Sodia."
EP Finance's combined companies (including Creapharm) have 160 staffers and projected turnover of $33 million in the 2013-14 fiscal year.